# US 2019/0375745 A1 · (hetero)arylamide compound for inhibiting protein kinase activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375745 A1
- Document ID: US20190375745A1
- Status: Published application
- Kind: A1
- Application number: 16/479,271
- Filed: 2018-01-19
- Published: 2019-12-12
- Earliest claimed: 2017-01-20
- Assignees: Shenzhen TargetRx, Inc.
- Applicants: Shenzhen TargetRx, Inc.
- Inventors: Yihan Wang; Jiuyang Zhao; Yixin Ai
- Web page: https://patentgrep.com/patent/US20190375745A1

## CPC

- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C07D 417/14: containing three or more hetero rings
- A61P 35/00: Antineoplastic agents
- C07D 401/14: containing three or more hetero rings
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs comprising an anti-tumour drug.

## Claims

### Claim at position 1

-13. (canceled)

### Claim 14

A compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof:
wherein:
Y1 is selected from CRa or N;
Y is independently selected from CRa or N;
R1 is selected from hydrogen, halo, nitrile, nitro, C1-6 alkyl or C1-6 haloalkyl, wherein the said C1-6 alkyl or C1-6 haloalkyl is optionally substituted by R1a group;
R2 is selected from hydrogen, C1-6 alkyl or C1-6 haloalkyl, wherein the said C1-6 alkyl or C1-6 haloalkyl is optionally substituted by R2a group;
Z is a chemical bond, O, S(O)0-2 or NRb;
or —Z—R2 together form —SF5;
Ar is
wherein X1 is S, X2 to X4 are independently selected from CR or N; and one of X2, X3 and X4 is C atom that connects the parent core; Het is
wherein X9 is selected from O, S, NRb or C(R)2;
m is 0, 1 or 2;
n is 0, 1, 2, 3, 4, 5 or 6;
Ra is independently selected from hydrogen, halo, nitrile, nitro, hydroxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, C1-6 alkyl, C1-6 haloalkyl or C1-6 alkoxyl;
Rb is independently selected from hydrogen, C1-6 alkyl or C1-6 haloalkyl;
R1a, R2a and R are independently selected from hydrogen, halo, hydroxy, —NH2, —NHC1-6 alkyl, —N(C1-6 alkyl)2, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, C3-7 cycloalkyl, C3-7 heterocyclyl, C6-10 aryl or C5-10 heteroaryl;
or two R groups on the same or adjacent atoms may together form C3-7 cycloalkyl, C3-7 heterocyclyl, C6-10 aryl or C5-10 heteroaryl.

### Claim 15 (depends on 14)

The compound according to claim 14, which is formula (la), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof:
wherein, Ar and Het are as defined in claim 14.

### Claim 16 (depends on 14)

The compound according to claim 14, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof, wherein:
Het is
wherein, X9 is C(R)2, and m, n and R are as defined in claim 14.

### Claim 17 (depends on 14)

The compound according to claim 14, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof, wherein, Het is selected from the following groups that are optionally substituted by one, two, three or more R:
wherein R are as defined in claim 14.

### Claim 18 (depends on 14)

The compound according to claim 14, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof, wherein, Het is selected from the following groups:

### Claim 19 (depends on 14)

The compound according to claim 14, which is formula (Ib), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof:
wherein:
Ar is selected from the following groups that are optionally substituted by one or two R:
R is selected from hydrogen, halo, hydroxy, —NH2, —NHC1-6 alkyl or —N(C1-6 alkyl)2.

### Claim 20 (depends on 14)

The compound according to claim 14, which is formula (Ib), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof:
wherein:
Ar is selected from the following groups that are optionally substituted by one or two R:
R is selected from hydrogen or hydroxy.

### Claim 21 (depends on 14)

The compound according to claim 14, which is formula (lb), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof:
wherein:
Ar is selected from the following groups that are optionally substituted by one or two R:
R is selected from hydrogen, halo, or hydroxy.

### Claim 22 (depends on 14)

The compound according to claim 14, which is formula (Ib), or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof:
wherein:
Ar is selected from the following groups that are optionally substituted by one or two R:
R is selected from hydrogen or hydroxy.

### Claim 23 (depends on 14)

The compound according to claim 14, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof, wherein the said compound is selected from:

### Claim 24 (depends on 23)

The compound according to claim 23, which is
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 23)

The compound according to claim 23, which is
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 23)

The compound according to claim 23, which is
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 23)

The compound according to claim 23, which is
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 14)

A pharmaceutical composition, comprising:
the compound according to claim 14 or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof, and
pharmaceutically acceptable excipients.

### Claim 29 (depends on 24)

A pharmaceutical composition, comprising:
the compound according to claim 24 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

### Claim 30 (depends on 25)

A pharmaceutical composition, comprising:
the compound according to claim 25 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

### Claim 31 (depends on 26)

A pharmaceutical composition, comprising:
the compound according to claim 26 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

### Claim 32 (depends on 27)

A pharmaceutical composition, comprising:
the compound according to claim 27 or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

### Claim 33 (depends on 14)

A method of treating and/or preventing Bcr-Abl mediated diseases in a subject, comprising administering to the subject a compound according to claim 14 or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a hydrate thereof.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the said Bcr-Abl mediated diseases is a proliferative disease selected from: solid tumor, sarcoma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumor, thyroid cancer, gastric cancer, rectal cancer, multiple myeloma, neoplasia, and other proliferative disease or proliferative diseases; or the Bcr-Abl mediated diseases is metastatic invasive cancer, virus infection, or CNS diseases.
